Investor Summary JOEY NEW YORK (OTC JOEY)

Transcription

1 Joey New York is divided into two distinct divisions; The LABB, Labb Aesthetic Beaty Bar and Joey New York Beaty Prodcts. There is a high degree of synergy between the beaty prodcts line and the LABB services. With decades of skincare experience, the Joey team believed it was only logical that they leverage their knowledge by employing a new concept in the injectables market, (Botox and Fillers). It's a concept called The LABB (Labb Aesthetic Beaty Bar). The LABB is focsed on eliminating nwanted wrinkles by exclsively performing Botox and filler injections, nothing else, no facials, no laser, jst Botox and fillers. This is a large segment of a $13 Billion-dollar market that has grown 6,400% since The concept is very simple; excellent technicians, standardized training, mltiple locations, consistent branding, incredibly low overhead and state of the art facilities with blk bying prchasing power. With more people searching for a yothfl look, Joey New York intends to lead them to it.

2 Investor Smmary JOEY NEW YORK (OTC JOEY) Joey New York: 2 divisions THE LABB & Joey New York Beaty Prodcts High degree of synergy between cosmetic line and The LABB services THE LABB (Labb Aesthetic Beaty Bar) Decades of skin care experience Employing a new concept in the injectables market Focsed on eliminating nwanted wrinkles by exclsively performing Botox and filler injections No facials, no lasers Excellent technicians, standardized training, mltiple locations, consistent branding Low overhead in state of the art facilities with blk bying power $13 Billion dollar market that has grown 6,400% since 1997

3

4

5 THE LABB: THE MISSION Deliver exceptional client experience Beaty enhancement throgh the se of ctting edge technology and aesthetic craftsmanship from convenient platform Poised to become foremost leader in Aesthetic service High qality injectables Most advanced technologies Tailored to individal patients Affordable pricing Exclsively injectables Streamline prchasing power Driving down costs Attractive option rather than visiting expensive cosmetic srgeons

6 THE MARKET Sotheast coastal market represents 2 nd largest injectable filler market in US (barely below California) 10 facilities identified to be opened in 2017 creating $5 million profit in 1 st 12 months Florida Boca Raton West Palm Beach Aventra Other select cities California and Las Vegas Additional 5 facilities in 2018 Total of 15 facilities yielding over $35 Million in profit Soth Beach-Miami location open since 2016 consistently booked with wait list Daytona Beach & Ft. Laderdale location all cash flow positive Consistently growing cstomer base with 85% retrn clients

7 2015 Highlights of Injectables Up 18.9 % INJECTABLES The needle reigns in 2015 As a semi-invasive procedral option, injectables allow fans to minimize wrinkles and other tell-tale signs of aging on a temporary basis withot going nder the knife Botlinm Toxin (Botox, Dysport, Xeomin) -p 18.9% -p 6,448.9% since ASAPS began srveying injectable data in Srpassed the 4 million procedres performed mark for the first time in 2015 Up 26.6% Hyalronic Acid (Jvaderm Ultra, Ultra Pls, Volma, Perlane, Restylane and Belotero) -Up 26.6% in 2015 alone -Srpassed the 2 million procedres performed mark for the first time in 2015 Calcim Hydroxylapatite (Radiesse) Up 15.3% -Up 15.3% in 2015, since secring FDA approval for hand rejvenation. -It is also sed to smooth moderate to severe facial wrinkles and folds sch as nasolabial folds. Sorce: American Society for Aesthetic Plastic Srgery

8 Qick Facts Americans spent more than $13.5 billion on combined srgical and non-srgical procedres in 2015 A $1.5 billion increase in expenditres for combined srgical and non-srgical procedres from Non-srgical procedres p 22% with 10,879,909 performed Combined srgical & non-srgical p 20% compared to 2015 A total of 12,792,377 procedres performed Injectables overall saw a 21% increase in 2015 Belotero, Botox, Dysport, Jvederm Ultra, Jvederm Ultra Pls, Perlane, Poly-L-Lactic acid, Radiesse, Restylane, Volma, Xeomin Injectables contine to be poplar across the board, inclding men with 438,513 Botlinm Toxin and 159,052 Hyalronic Acid injections performed in 2015 Sorce: American Society for Aesthetic Srgery

9

10 What sets p apart.value High qality aesthetic services at affordable price points High qality, evidence based aesthetic services are performed by a Nrse Practitioner who specializes in injectables By performing injectables exclsively and keeping a small prodct portfolio we can streamline prchasing power and drive down prodct cost Combining low operational overhead and optimizing or manfactring rebates we can offer amazing pricing for top tier prodcts Redced price points makes The LABB extremely competitive in the market Will fill middle margin to optimize or cstomers VALUE and maximize the Retrn on Investment Low cost, high margin High Qality: Only FDA approved prodcts prchased directly from the manfactrers The LABB only ses evidence based practices and on-label procedres The American Academy of Aesthetic Medicine has 3 levels of board certification for the injecting of Botox The LABB will se only Board Certified and specially trained providers who specialize in injectable treatments The LABB facilities are state of the art and licensed & registered with all compliance entities

11 THE LABB: VALUE ADDED Expertise & Ability to combine medical and retail Minimize Risk & Optimize Safety Depth of knowledge of the markets & direct to consmer Prodct Prchasing Power & Redced Pricing Original Model Scheme

12 Sorce: American Society for Aesthetic Plastic Srgery Percent of Change in Select Procedres: Nonsrgical Note that large percentage changes are common in cases Where the total nmber of procedres is small Nonsrgical Procedre Injectables Percent Change 2015 vs 2014 Percent Change 2015vs Totals With Phys Ext. Botlinm Toxin (inclding Botox, Sysport, Xeomin) 4,267,038 3,688,218 65, % % 6.706,339 Calcim Hydroxylapatite (Radiesse) 163, ,059 n/a 15.3% n/a 226,020 Hyalronic Acid (incl. Jvederm Ultra, Ultra Pls, Volma, Perlane, Restylane, Belotero) 2,148,326 1,696,621 n/a 26.6% n/a 2,824,252 Poly-L-Latic Acid (Solptra) 82, ,313 n/a 4.4% n/a 102,356 Totals - Injectables 6,651,62 0 5,497, , % 6448% 8,857,968 n/a = Not available (was not collected in that year s srvey Hair transplantation, Polymethylacrylateand Celllite treatment were exclded from the reslts de to an insfficient sample of responding physicians who perform those procedres Percent Change totals are based on procedres for which data were collected in both years

13 Sorce: American Society for Aesthetic Plastic Srgery 2015 National Totals for Cosmetic Procedres - Nonsrgical Nonsrgical Procedre Injectables Nmber of Procedres 2015 Rank within Category (non-srgical) Botlinm Toxin (inclding Botox, Sysport, Xeomin) 4,267,036 1 Calcim Hydroxylapatite (Radiesse) 153, Hyalronic Acid (incl. Jvederm Ultra, Ultra Pls, Volma, Perlane, Restylane, Belotero) 2,148,326 2 Poly-L-Latic Acid (Solptra) 82, Totals - Injectables 6,651,620 NOTES Botlinm Toxin, (Botox, Dysport and Xeomin) and Hyalronic Acid, (Jvederm Ultra, Ultra Pls, Volma, Perlane, Restylane and Belotero) have maintained the #1 and #2 spots for most poplar nonsrgical procedres for seven years rnning

14 2015 Age Distribtion for Cosmetic Procedres Age 18 and nder 1.6% Age Age % 40.6% Percent of Total Nonsrgical Procedres By Age Age % Age % Total Poplation (ronded)=100% Sorce: American Society for Aesthetic Plastic Srgery

15

16 Headqarters Location Trmp Tower Collins Avene, Site 3202 Snny Isles Beach, FL Symbol: OTC JOEY Key Management Joey Chancis, Fonder/CEO Richard Roer, President

17 Crrent & Projected Performance The company expects to be profitable by the end of 2017 with accelerated growth and expected revenes of more than $5M Ftre expectation of earnings beyond 2017, driven by increased consmer demand for healthy skin care prodcts, is expected to be more than $9M on gross margins nearing 50% and net margins above 11%, on par with indstry standards